Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Biotech
Merck inks $1.6B-plus exclusive licensing pact with Orion
Merck is putting more than $1.6 billion biobucks on the table for Orion's cancer candidates targeting CYP11A1.
Gabrielle Masson
Jul 1, 2024 10:38am
Prostate cancer? Ptooey! Saliva test detects aggressive tumors
Jun 3, 2024 1:30pm
ASCO: J&J's radioligand spurs responses, but 4 deaths mar data
May 24, 2024 10:51am
MacroGenics' stock crashes after 5 deaths in ADC trial
May 10, 2024 6:00am
Novartis pays $150M for Arvinas' prostate tumor protein degrader
Apr 11, 2024 8:04am
Prostate cancer ADC breaks FibroGen's clinical losing streak
Apr 3, 2024 10:55am